123 related articles for article (PubMed ID: 9611049)
1. Biologic prognostic factors in ovarian cancer: a review.
Framarino dei Malatesta ML; Veneziano M; Peppicelli M; Lanzi G; Marzetti L
Eur J Gynaecol Oncol; 1998; 19(2):123-5. PubMed ID: 9611049
[TBL] [Abstract][Full Text] [Related]
2. [Histopathologic prognostic factors, serum markers and selected molecular biologic factors in ovarian carcinoma].
Spacek J; Jílek P; Petera J; Tesarík Z
Ceska Gynekol; 2002 Nov; 67(6):343-9. PubMed ID: 12661373
[TBL] [Abstract][Full Text] [Related]
3. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma.
Karihtala P; Soini Y; Vaskivuo L; Bloigu R; Puistola U
Int J Gynecol Cancer; 2009 Aug; 19(6):1047-51. PubMed ID: 19820366
[TBL] [Abstract][Full Text] [Related]
4. The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer.
Baekelandt M; Holm R; Tropé CG; Nesland JM; Kristensen GB
Ann Oncol; 1999 Nov; 10(11):1335-41. PubMed ID: 10631462
[TBL] [Abstract][Full Text] [Related]
5. Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma.
Labiche A; Heutte N; Herlin P; Chasle J; Gauduchon P; Elie N
Int J Gynecol Cancer; 2010 Jan; 20(1):28-33. PubMed ID: 20130500
[TBL] [Abstract][Full Text] [Related]
6. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.
Bi R; Shen X; Zhang W; Cheng Y; Feng Z; Cai X; Yang W
Diagn Pathol; 2016 Feb; 11():17. PubMed ID: 26837693
[TBL] [Abstract][Full Text] [Related]
7. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
9. Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.
Aman M; Ohishi Y; Imamura H; Shinozaki T; Yasutake N; Kato K; Oda Y
Hum Pathol; 2017 Jun; 64():156-163. PubMed ID: 28438620
[TBL] [Abstract][Full Text] [Related]
10. Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance.
Suzuki M; Ohwada M; Saga Y; Kohno T; Takei Y; Sato I
Oncology; 2001; 60(2):170-5. PubMed ID: 11244333
[TBL] [Abstract][Full Text] [Related]
11. Contribution of immunohistochemistry in prognostic assessment of epithelial ovarian carcinoma --review of the literature I.
Tomsová M; Melichar B
Acta Medica (Hradec Kralove); 2006; 49(3):161-5. PubMed ID: 17117604
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
13. Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationship with histopathology and prognosis.
Ghazizadeh M; Ogawa H; Sasaki Y; Araki T; Aihara K
Hum Pathol; 1997 Aug; 28(8):960-6. PubMed ID: 9269833
[TBL] [Abstract][Full Text] [Related]
14. P16INK4a overexpression is associated with poor clinical outcome in ovarian carcinoma.
Raspollini MR; Amunni G; Villanucci A; Baroni G; Taddei GL
J Chemother; 2004 Aug; 16(4):411-3. PubMed ID: 15332720
[No Abstract] [Full Text] [Related]
15. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.
Henriksen R; Funa K; Wilander E; Bäckström T; Ridderheim M; Oberg K
Cancer Res; 1993 Oct; 53(19):4550-4. PubMed ID: 8402626
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer.
Anttila M; Kosma VM; Ji H; Wei-Ling X; Puolakka J; Juhola M; Saarikoski S; Syrjänen K
J Clin Oncol; 1998 Aug; 16(8):2591-600. PubMed ID: 9704708
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions.
Bock AJ; Stavnes HT; Kempf T; Tropè CG; Berner A; Davidson B; Staff AC
Int J Gynecol Cancer; 2010 Dec; 20(9):1448-55. PubMed ID: 21336029
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.
Xu Y; Wang C; Zhang Y; Jia L; Huang J
Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
